Dr. Dhankhar currently serves as the HEOR lead at CHEORS, where his primary responsibility is the adaptation of models to support reimbursement efforts. Prior to joining CHEORS, he worked in the pharmaceutical industry and Center for Disease Control as a health economist for nearly 10 years. Dr. Dhankhar has worked extensively in multiple disease areas including vaccines, oncology, diabetes, cardiovascular diseases, infectious diseases, and ultra-rare diseases. He is an expert in economic modeling, country submissions for HTA review, and developing strategy to generate value evidence for products. He has launched products both globally and in US and has extensive experience in working with country affiliates. He has helped countries understand various economic models, created input sheets to be shared with countries, and assisted countries with collecting data for model inputs. He has also generated reports and slide decks based on the model analysis to be shared with the countries.
PHD – VICE PRESIDENT, HEOR
Dr. Bagga is Senior Director, HEOR, at CHEORS. Prior to joining CHEORS, she worked in the pharma industry, consulting, and Centers for Disease Control and Prevention (CDC) for more than 12 years. She has worked extensively in multiple disease areas including vaccines, pain management, respiratory, and biologics. Shalini has helped to conduct multi-country studies worldwide and collect data. She has helped to launched products both globally and in the US and has extensive experience in working with country affiliates. She currently leads the systematic literature review, meta-analysis, and dossier creation at CHEORS.
PHD – VICE PRESIDENT, VALUE COMMUNICATION
PHD – VICE PRESIDENT, ECONOMIC MODELING
Dr. Cook currently serves as Vice President for Economic Modeling at CHEORS. In this capacity, he is responsible for overseeing the development of all new health economic models at CHEORS, and personally directs many of them. Prior to joining CHEORS, John served as Executive Director and headed (for 15 years) the Health Economic Statistics Department in CORE at Merck & Co., Inc. Dr Cook and his team were responsible for the development and adaptation of health economic models to project the long-term impact of treatment on health outcomes and cost. John also gained valuable experience analyzing clinical trial data for economic purposes. With nearly 30 combined years of experience, he is an expert in developing and guiding teams to develop cost-effectiveness and budget impact models and in capitalizing on clinical trial data for health economic purposes. Dr. Cook has published over 40 articles, book chapters and reviews in health economics and statistics and has taught short-courses on conducting economic evaluations at several venues, including the Joint Statistical Meetings, International Society of Pharmacoeconomics and Outcomes Research (ISPOR) conferences, International Health Economics Association Conference, and at the Stockholm School of Economics. He also served on two ISPOR Good Research Practices Task Forces – for Randomized Clinical Trial-Cost Effectiveness Analysis (RCT-CEA) and for Economic Data Transferability.
Dr. Dhanda currently serves as the Real-World Evidence (RWE) lead at CHEORS, where his primary responsibility is the generation of evidence from observational studies that utilize either databases, patient registries, or pragmatic trials. Prior to joining CHEORS, he worked in the pharmaceutical, biotech, and medical device sectors of the industry, and with contract research organizations. Dr. Dhanda also holds an adjunct associate professorship with the University of Texas Health Science Center in San Antonio. Having worked in different segments of the health care industry for over 25 years, he has developed a diverse background that underlies his analytical capabilities to understand, execute and produce quality work on high priority projects. Dr. Dhanda has worked in multiple therapeutic areas including, oncology, CNS, cardiovascular diseases, dermatology, pain, infectious diseases, and rare diseases. He is an expert in the use of statistical methods to analyze data. He is on the editorial board of an applied statistical journal and has been a peer reviewer for several academic journals. He is also actively engaged with ISPOR, ISPE, and ISOQOL. He has published his research in many peer reviewed journals, and presented his research findings at various medical conferences.
PHD – VICE PRESIDENT, REAL-WORLD EVIDENCE
MBA – DIRECTOR, HEOR & REIMBURSEMENT
Michael Marentette is Director, HEOR & Reimbursement, and the Canada Country Lead for CHEORS. Michael has over 20 years of experience in Market Access and HEOR in the pharmaceutical industry, including 15 years at Merck Canada and Janssen and over 5 years of consulting experience. Michael has demonstrated leadership and high performance in shaping and delivering value propositions to fully leverage the reimbursement potential of Government and private sector formulary listings across Canada in multiple therapeutic areas for a number of pharmaceutical and biologic products, including some of the industry’s biggest brands. Michael has led the planning and development of multiple Health Economics models, Budget Impact Analyses and Outcomes Research studies, several of which resulted in peer-reviewed publications. Michael has held several senior management roles, including Director of Reimbursement with Merck Canada, and has served on global Market Access planning committees.
Bridget Corbett is the Associate Director of Business Development at CHEORS with more than 15 years of sales and marketing experience, 7 of which have been in the pharmaceutical industry. Prior to joining CHEORS, she was an Account Director at SDI Health (now called IQVIA) where she was responsible for selling prescription and diagnosis data. She also spent some time as an Account Director for an IT consultancy helping her clients integrate field force and market research data into mobile and web applications. Her current position at CHEORS has given her the opportunity to learn HEOR and Market Access and to identify opportunities for the company to work with new clients.
ASSOCIATE DIRECTOR OF BUSINESS DEVELOPMENT
“Thank you for this. This is great work!”
Principal Scientist,Biopharmaceutical Company
“I am very happy working with the CHEORS team. CHEORS stands out in particular in the area of communication and responsiveness. I always feel assured that there is no misunderstanding.”
Assoc. Director,Biopharmaceutical Company
“I am most pleased to work with CHEORS. We managed early deadlines with high-quality end results.”
Specialist,Outcomes Research/Medical Affairs
"With aspect of technical knowledge, communication and responsiveness, CHEORS is fantastic. I am very happy with your work. Frankly, you have over-delivered than what I expected"
HTA Manager,Biopharmaceutical Company
“CHEORS is experienced and found solutions to all issues we faced during the preparation time. Communication was very precise and strict—we were happy to work with the team.”